Truist raises Nurix Therapeutics price target to $32

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Truist Securities analyst Gregory Renza maintained a Buy rating on Nurix Therapeutics, raising the price target to $32 from the previous $30.

powered bylight_fuzz_icon
42550776

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Gregory Renza has maintained a Buy rating on Nurix Therapeutics and raised the price target for the stock. The new target of $32 represents an increase from the previous $30.

Rating and Target Update

The analyst's decision to maintain the Buy rating accompanies the revised price objective. The adjustment reflects a positive outlook on the company's performance.

Metric Value
Rating Buy
Previous Price Target $30
New Price Target $32
Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts or data points are expected to drive the stock toward the new $32 price target?

How might this rating update influence investor sentiment and trading volume in the short term?

What are the potential risks or market conditions that could prevent Nurix Therapeutics from meeting this revised target?

like20
dislike

Jefferies maintains Buy on Nurix Therapeutics, raises target to $45

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Jefferies analyst Roger Song maintained a Buy rating on Nurix Therapeutics and raised the price target to $45 from $41, indicating a positive outlook on the stock.

powered bylight_fuzz_icon
42492912

*this image is generated using AI for illustrative purposes only.

Jefferies analyst Roger Song has maintained a Buy rating on Nurix Therapeutics, citing an updated valuation. The firm increased the price target for the stock to $45, up from the previous target of $41.

Rating and Target Details

The revised price target reflects a more optimistic outlook on the company's performance. The decision to retain the Buy rating suggests confidence in the stock's potential to deliver returns above the market average.

Metric Value
Rating Buy
Previous Price Target $41
New Price Target $45

The adjustment comes as the analyst evaluates the company's current market position and future growth prospects.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific catalysts or data readouts are expected to drive the stock toward the new $45 price target?

How does Nurix Therapeutics' current pipeline progress compare to its competitors in the targeted therapy space?

What are the potential risks or market headwinds that could prevent the company from meeting this revised valuation?

like16
dislike